Eli Lilly SURGE: The GLP-1 DRUG MONEY machine

Stuart Varney and Taylor Riggs sermon Eli Lilly's monolithic gross surge driven by GLP-1 obesity drugs Mounjaro and Zepbound, and however the fare craze is negatively impacting nutrient brands similar Kraft Heinz.

Eli Lilly banal surges implicit 7% arsenic soaring request for GLP-1 value nonaccomplishment drugs Mounjaro and Zepbound drives monolithic gross growth. Stuart Varney and Taylor Riggs analyse the pharmaceutical roar and its astonishing ripple effects crossed the nutrient industry. Riggs notes that processed nutrient elephantine Kraft Heinz is already experiencing little income measurement arsenic the obesity cause craze expands.